Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound by Cook, Jacquelynn J et al.




Acute gamma-secretase inhibition of nonhuman
primate CNS shifts amyloid precursor protein
(APP) metabolism from amyloid-beta production












This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Cook, Jacquelynn J.; Wildsmith, Kristin R.; Gilberto, David B.; Holahan, Marie A.; Kinney, Gene G.; Mathers, Parker D.; Michener,
Maria S.; Price, Eric A.; Shearman, Mark S.; Simon, Adam J.; Wang, Jennifer X.; Wu, Guoxin; Yarasheski, Kevin E.; and Bateman,
Randall J., ,"Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from
amyloid-beta production to alternative APP fragments without amyloid-beta rebound." The Journal of Neuroscience.30,19.
6743-6750. (2010).
http://digitalcommons.wustl.edu/open_access_pubs/274
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons
Authors
Jacquelynn J. Cook, Kristin R. Wildsmith, David B. Gilberto, Marie A. Holahan, Gene G. Kinney, Parker D.
Mathers, Maria S. Michener, Eric A. Price, Mark S. Shearman, Adam J. Simon, Jennifer X. Wang, Guoxin Wu,
Kevin E. Yarasheski, and Randall J. Bateman
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/274
Neurobiology of Disease
Acute -Secretase Inhibition of Nonhuman Primate CNS
Shifts Amyloid Precursor Protein (APP) Metabolism from
Amyloid- Production to Alternative APP Fragments
without Amyloid- Rebound
Jacquelynn J. Cook,3* Kristin R. Wildsmith,1* David B. Gilberto,4Marie A. Holahan,3 Gene G. Kinney,5
Parker D. Mathers,4Maria S. Michener,3 Eric A. Price,5Mark S. Shearman,5 Adam J. Simon,5 Jennifer X. Wang,2
GuoxinWu,5 Kevin E. Yarasheski,2 and Randall J. Bateman1
Departments of 1Neurology and 2Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, and Departments of 3Imaging,
4Laboratory Animal Resources, and 5Neuroscience, Merck Research Laboratories, West Point, Pennsylvania 19486
The accumulation of amyloid  (A) in Alzheimer’s disease is caused by an imbalance of production and clearance, which leads to
increased soluble A species and extracellular plaque formation in the brain. Multiple A-lowering therapies are currently in develop-
ment: an important goal is to characterize the molecular mechanisms of action and effects on physiological processing of A, as well as
other amyloid precursor protein (APP) metabolites, in models which approximate human A physiology. To this end, we report the
translation of the human in vivo stable-isotope-labeling kinetics (SILK) method to a rhesus monkey cisterna magna ported (CMP)
nonhuman primate model, and use the model to test the mechanisms of action of a -secretase inhibitor (GSI). A major concern of
inhibiting the enzymeswhich produceA (- and-secretase) is that precursors of Amay accumulate and cause a rapid increase inA
productionwhen enzyme inhibitiondiscontinues. In this study, theGSIMK-0752was administered to consciousCMP rhesusmonkeys in
conjunction with in vivo stable-isotope-labeling, and dose-dependently reduced newly generated CNS A. In contrast to systemic A
metabolism, CNS A production was not increased after the GSI was cleared. These results indicate that most of the CNS APP was
metabolized toproducts other thanA, includingC-terminal truncated formsofA: 1-14, 1-15 and1-16; this demonstrates analternative
degradation pathway for CNS amyloid precursor protein during -secretase inhibition.
Introduction
The amyloid hypothesis proposes that the accumulation of
amyloid- (A) in the brain leads to a cascade of events cul-
minating in Alzheimer’s disease (AD) (Hardy and Selkoe,
2002; Golde, 2005). A is generated by the sequential cleavage
of amyloid precursor protein (APP) by -secretase and
-secretase (Blennow et al., 2006; Steiner et al., 2008; Wolfe,
2008b). A accumulation in the form of insoluble plaques and
soluble monomers and oligomers develops due to an imbal-
ance in the production and clearance of these A forms in the
CNS.
Because A is a major therapeutic target, multiple A-lowering
strategies are under development, such as increasing clearance (in-
cludingA immunization approaches) or decreasingproductionby
inhibition of-secretase or-secretase (Hock et al., 2003; Lemere et
al., 2004; Vassar, 2004;Wolfe, 2008a; Tomita, 2009).-Secretase is a
complex of integral membrane proteins that are present in most
cells, but may have different functions depending on cell type
(Steiner et al., 2008). -Secretase inhibitors (GSIs) target the
-secretase complex to inhibit the production of A from the -C-
terminal fragment of APP. However, GSIs also inhibit notch pro-
cessing, thereby interferingwith the critical role of notch in signaling
cell differentiation in the immune system and gastrointestinal tract
(Maillard et al., 2003; Stanger et al., 2005). Chronic inhibitionwith a
GSI leads to mechanism-based toxic side-effects (Searfoss et al.,
2003; Wong et al., 2004), which may be avoided by using partial or
intermittent-secretase inhibition.However, there is a concern that
when -secretase inhibition is partial or intermittent, accumulated
APP products, including the -C-terminal fragment, will result in
A overshoot or rebound.
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After GSI treatment, a rebound in levels of A above placebo
is consistently observed in plasma of humans and animal models
(Lanz et al., 2004, 2006; Michener et al., 2006; Rosen et al., 2006;
Siemers et al., 2006). In addition, an early elevation in plasma
A40 has also been observed in rhesusmonkeys at GSI doses that
do not reduce plasma A40 (Michener et al., 2006). Although an
overshoot was reported in the CNS of a rat model (Burton et al.,
2008), it has not been observed in the CNS of human volunteers
(Rosen et al., 2006) or other animal models (Lanz et al., 2004).
The contrasting results observed in plasma versus the CNS high-
light the separation of the periphery from the CNS and indicate
potentially different molecular mechanisms of A production
and APP processing. As increased concentrations of A in the
CNS are expected to be harmful, it is important to demonstrate
that candidate compounds are truly targeting A generation in
the CNS. Clarification of the specific effect on the processing of
APP metabolites is also important for the selection of optimal
compounds for development. As few treatments or conditional
experiments can be evaluated in humans, we translated a recently
described stable-isotope-labeling kinetic (SILK) method (Bateman
etal., 2006) toanonhumanprimatemodel for testingof therapeutics
and molecular mechanisms. By administering stable-isotopes in
conjunction with a GSI, the effect of inhibition on A production
was measured by liquid chromatography tandem mass spectrome-
try (LC-MS/MS). Similar to results seen in humans (Bateman et al.,
2009), there was a dose-related decrease in A production in re-
sponse to -secretase inhibition without an overshoot of either
newly generated or total levels of A.
Materials andMethods
Cisternamagna ported rhesus monkeymodel.All procedures related to the
use of animals in these studies were reviewed and approved by the Insti-
tutional Animal Care and Use Committee at Merck Research Laborato-
ries at West Point, and conform with the Guide for the Care and Use of
LaboratoryAnimals (Institute of LaboratoryAnimal Resources,National
Research Council, 1996). The chronically implanted cisterna magna
catheter and port system provides for noninvasive collection of uncon-
taminated CSF samples and the capability for repeat sampling. This
chronic system allows for longitudinal studies and comparison to histor-
ical data within the same monkeys. A customized flexible silicone cathe-
ter (SoloCath) is freely suspended in the cisternamagna, anchored firmly
on both sides of the atlanto-occipital membrane, and tunneled subcuta-
neously to the midscapular region where it is fed into a surgically im-
planted port body. CSF is accessed by aseptically inserting a needle
through the skin and membrane covering the port into the reservoir of
the port body (Gilberto et al., 2003); CSF flows through the cannulation
system without the need for active withdrawal. These monkeys are also
implanted with a standard catheter system in the jugular vein (titanium
vascular access port by SoloPort) for chronic vascular access used for the
13C6-leucine infusions.
13C6-Leucine infusion protocol. In preparation for each experiment,
rhesus monkeys were restricted to a diet of vegetables and fruit for a 24 h
period before the start of the 13C6-leucine infusion; all foodwas removed
17 h before dosing. Vegetables and fruit were provided again after the
8 h sample collection (during the infusion) and the normal diet of mon-
key chow (includes protein) was given after the termination of the infu-
sion (12 h in the final standard protocol). Conscious monkeys were
transferred to the laboratory and placed in primate restraint chairs; a 22 g
Huber needle (Instech) connected to a sterile adapter was inserted into
the port body to prepare the cisterna magna catheter and port system for
CSF sampling. A sterile stock solution of 13C6-leucine (Cambridge Iso-
tope Laboratories, CLM-2262) was made fresh daily for each study at 15
or 7.5 mg/ml in saline for the high (8 mg/kg  8 mg/kg/h) and low (4
mg/kg  4 mg/kg/h) leucine infusions, respectively. The 13C6-leucine
was infused in the chronic vascular access port at0.5 ml/min or0.1
ml/min for the bolus and 12 or 21 h infusions (exact rate was normalized
for body weight). Baseline CSF and blood samples were collected 1 h
before the start of the 10 min primed bolus injection. In the final, opti-
mized (12 h) protocol, plasma and CSF samples were also collected fol-
lowing the initiation of the 13C6-leucine infusion at 2 h (11:00 A.M.), 4 h
(1:00 P.M.), 6 h (3:00 P.M.), 8 h (5:00 P.M.), 12 h (9:00 P.M., end of
infusion), 15 h (12:00 A.M.), 18 h (3:00 A.M.), 21 h (6:00 A.M.), 24 h
(9:00 A.M., day 2), 27 h (12:00 P.M.), 30 h (3:00 P.M.), 33 h (6:00 P.M.),
36 h (9:00 P.M., day 3) and 39 h (12:00 P.M.). CSF (1 ml) was collected
per time point, and samples were separated into aliquots and transferred
to various laboratories for blinded analyses.
-Secretase inhibitor study protocol. The Merck -secretase inhibitor,
MK-0752, was previously characterized for in vivo pharmacokinetics and
efficacy, and demonstrated decline of CSF A40 levels in healthy human
volunteers (Rosen et al., 2006). MK-0752 is a moderately potent
-secretase inhibitor, showing dose-dependent reduction of A40 with
an IC50 of 5 nM in human SH-SY5Y cells. Dose-dependent reductions in
plasma, brain and CSF A40 were observed in guinea-pigs following
single oral doses of 10–30 mg/kg (brain IC50 440 nM). Concentration
required for 50% reduction of brain A40 was 318 and 154 nM in APP-
YAC and Tg2576 mice, respectively. For the purposes of the current
study, 60 and 240 mg/kg dose of MK-0752 were selected to elicit inter-
mediate and near complete CSF A reduction for evaluating the poten-
tial effects on A production and clearance. A 3-way crossover
randomized design with 2 week intervals between doses in cisterna
magna ported (CMP) rhesus monkeys was used (n  6 male rhesus
monkeys; n 5 at 6–9 years and n 1 at 17 years at time of study; 7–9.5
kg). MK-0752 (60 or 240 mg/kg) or vehicle (water) was administered
orally to conscious, chaired rhesus monkeys 1 h before the initiation of
the primed 12 h 13C6-leucine constant infusion (4 mg/kg 4 mg/kg/h).
CSF and plasma samples were collected as described above for determi-
nation ofMK-0752 concentrations, A40 (ELISA), 13C6-leucine labeling
of A, and free 13C6-leucine enrichment.
To fully characterize the rebound beyond baseline in plasma A40, a
follow-up study was conducted. Six rhesus monkeys (n 3/group) were
treated orally with vehicle or 240mg/kgMK-0752. CSF and plasma sam-
ples were collected as described for the optimized protocol with the ad-
dition of time points through 240 h postdose (48, 72, 144, 168, 216,
240 h).
Amyloid  ELISA. Solid black 96 well Nunc plates were coated with 3
g/ml N-terminal A antibody 6E10 (Signet) in pH 9.4 bicarbonate
buffer overnight at 4°C, washed with PBS with 0.1% Tween 20, and
blocked with 3% BSA in PBS (BSA/PBS) for 3 h. CSF samples for the
A1-40 assay were diluted 1:8 in BSA/PBS; 50 l of samples and stan-
dards, starting at 4:00 P.M., were loaded onto the plate. CSF samples for
A1-42 were diluted 1:4 in BSA/PBS and 100 l of samples and stan-
dards, starting at 2:00 P.M., were loaded onto the plate. Plasma samples
were diluted 1:4 in BSA/PBS and 50l of samples and standards, starting
at 4:00 P.M., were loaded onto the plate. Fifty microliters of G2-10-
alkaline phosphatase (A1-40) or 12F4-alkaline phosphatase (A1-42)
diluted in BSA/PBS was added to the plate and incubated overnight at
4°C. Plates were washed 3 times in PBSwith 0.1%Tween 20 and 100l of
alkaline phosphatase substrate Tropix CDP-star (Applied Biosystems)
was added for 30 min. Luminescence was measured using a PerkinElmer
Envision plate reader.
Amyloid  immunoprecipitation. Antibody beads were prepared by
covalently binding 4G8 antibody (GE Healthcare) (recognizes A resi-
dues 18-22) or 6E10 antibody (Covance) (recognizes A residues 1-17)
to CNBr Sepharose beads (GE Healthcare) at a concentration of 10
mg/ml antibody (according to the manufacturer’s protocol). The anti-
body beads were stored at 4°C in a 50% slurry of PBS 0.02% azide.
4G8 immunoprecipitation. CSF (500 l) was diluted 1:1 with PBS.
Protease inhibitors (40 g/ml aprotinin and 20 g/ml leupeptin) (Cal-
biochem), 30 l of antibody-bead slurry, and guanidine (final concen-
tration of 0.5 M) in Tris-HCl buffer pH 8 were added to the diluted CSF,
and samples were rotated overnight at 4°C. The beads were rinsed once
with 0.5 M guanidine and twice with 25 mM ammonium bicarbonate,
with centrifugation in between rinses. They were aspirated dry after the
final rinse and A was eluted from the antibody–bead complex using 50
l of neat formic acid. After centrifuging the beads again, the formic acid
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supernatant was transferred to a new tube and evaporated in a rotary
evaporator at 37°C for 30 min. The dried extract was reconstituted in 20
l of 9:1 ammonium bicarbonate (25 mM): acetonitrile. The extract was
digested with 400 ng of sequence grade trypsin (Promega) prepared in 25
mM ammonium bicarbonate and incubated at 37°C for 18 h.
6E10 immunoprecipitation. Protease inhibitors and guanidine were
added to CSF (900 l) as described above. In addition, samples were
spiked with 100 fmol (10 fmol/l) of isotope-labeled A peptide
A1-15[Ala(U- 13C3,




(prepared in HPLC grade water) (Anaspec) before addition of 30l of
6E10 bead slurry, after which they were rotated overnight at 4°C. The
beads were rinsed as described above and peptides and proteins were
eluted from the antibody–bead complex using 50 l of neat formic
acid. After centrifugation, the formic acid supernatant was trans-
ferred to autosampler vials and evaporated in a rotary evaporator at
37°C for 30 min. The dried extract was reconstituted in 20 l of 5%
acetonitrile in 0.1% formic acid.
Liquid chromatography-mass spectrometry. A extracts were analyzed
on a Thermo-Finnigan LTQ equipped with a New Objective nanoflow
ESI source. Peptides were separated by RP HPLC using an Eksigent
2D-LC nanoflow pump operating in 1D mode at a flow of 200 nl/min.
Five microliters of extract was injected onto a New Objective picofrit
column packed to 10 cm with 5 m Magic C18aq packing material
(Michrom). Mobile phase A consisted of 0.1% formic acid in water, and
mobile phase B consisted of 0.1% formic acid in acetonitrile. The doubly
charged species of A 17-28 were separated as previously described
(Bateman et al., 2007b). The quadruply charged species of A1-14, 1-15,
1-16, and 1-17 were separated by applying a linear gradient from 2 to
18% B over 30min, followed by a rise to 90% B over 5min, and returned
to 2% B by 40 min.
Calculation of labeled protein ratio and quantitation of A1-14, 1-15,
1-16, and 1-17. Percentage of labeled A was calculated as the ratio of all
b- and y-tandem MS ion intensities from 13C6-A 17–28 (m/z 666.5)
divided by all b- and y-tandem MS ion intensities from A 17–28 (m/z
663.5) as previously described (Bateman et al., 2007b). The peak areas for
A1-14, 1-15, 1-16, and 1-17 (MS2 total ion currents) were calculated
and normalized to the A1-15 isotope-labeled standard using Xcalibur’s
quantitation software. Results were exported to MS Excel. All statistical
calculations were performed with GraphPad
5.0. The coefficient of variation for quantita-
tion was 3.8% for triplicate injections of the
same sample.
Gas chromatography-mass spectrometry and
calculation of 13C6-leucine enrichment. Plasma
and CSF 13C6-leucine enrichment was quanti-
fied using capillary gas chromatography mass
spectrometry (GC-MS; Agilent 6890N gas
chromatograph and Agilent 5973Nmass selec-
tive detector). Leucine was converted to the
heptafluorobutyric propyl ester derivative;
13C6-leucine (m/z 349 and 355) enrichment
was quantified usingGC-MS in negative chem-
ical ionization mode (Yarasheski et al., 1992;
Batemanet al., 2007b). 13C6-Leucineenrichment
was calculated as the tracer:tracee ratio (Wolfe et
al., 2005). The GC-MS instrument response was
calibrated using gravimetric standards of known
isotope enrichment.
Calculations of fractional synthesis rate, frac-
tional clearance rate, and newly generated A.
The fractional synthesis rate (FSR) and frac-
tional clearance rate (FCR) were calculated in
the traditional manner (Wolfe et al., 2005).
FSR equals the slope of the labeled A (hours
2–8) divided by plasma 13C6-leucine enrich-
ment (precursor pool for A synthesis) during
leucine infusion (hours 2–8). FCR equals the
slope of the natural logarithm of labeled A
during the clearance phase (hours 18–33).
Newly generated A was calculated as previ-
ously described as the product of the percentage of labeled A (LC-MS
results) and the total A concentration (ELISA results) (Bateman et al.,
2009). All statistical calculations were performed with GraphPad 5.0.
Results
Translation of human CNS-SILKmethod for use in
rhesus monkeys
We adapted the human in vivo SILK method for use with CMP
rhesusmonkeys. A summary of the protocol is shown in Figure 1.
13C6-Leucine is intravenously administered to CMP rhesusmon-
keys for 12 h; CSF is collected from the cisterna magna port
during andafter administration (Fig. 1A,B). Labeled leucine enrich-
ment in plasma and CSF is measured by GC-MS (Yarasheski et al.,
1992) (Fig. 1C).The incorporationof the label intoA is quantitated
by immunoprecipitation paired with LC-MS (Bateman et al., 2006,
2007b) (Fig. 1D), and the results are used to calculate production
and clearance rates.
To translate the in vivomethod fromhumans tomonkeys, and
to achieve similar 13C6-A labeling, two
13C6-leucine infusion
protocols were evaluated. CMP rhesus monkeys were infused
with 13C6-leucine (8 mg/kg/h) for either 21 or 12 h, and CSF was
collected approximately every 3 h for up to 48 h (Fig. 2). The
administration of 8 mg/kg/h 13C6-leucine resulted in fourfold
higher plasma 13C6-leucine labeling than the ratios observed in
humans (Bateman et al., 2006). Reduction of the infusion to 4
mg/kg/h 13C6-leucine for 12 h resulted in maximum plasma
13C6-leucine labeling of 15%, which is more similar to human
studies, and thus was used for subsequent studies. The steady-
state labeling of A exceeded the theoreticalmaximumwhenCSF
13C6-leucine levels were used as the precursor pool (Fig. 2A, 21 h
infusion). In contrast, the steady-state labeling of A approached
and did not exceed the maximum when using plasma 13C6-
leucine levels (Fig. 2B, 21 h infusion). For this reason, subsequent
studies used plasma 13C6-leucine levels for labeled A normaliza-
Figure 1. Illustration of A stable-isotope-labeling kinetics study in CMP rhesusmonkeys. A, CSF is collected from the cisterna
magna of the rhesusmonkey.B, 13C6-leucine is infused from 0 to 12 h, and CSF collected from1 to 48 h. C,
13C6-leucine (Leu) is
present in the plasma for the duration of infusion.D, The 13C6-leucine-labeled A in rhesusmonkey CNS increases during labeling
(production phase) and decreases thereafter (clearance phase).
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tion. By reducing the 13C6-leucine infusion
from 21 to 12 h, more sample time points
could be added to the A clearance phase
which enabledmore accurate clearance rate
calculations.
Intrasubject and intersubject variabil-
ity for measurements of A metabolism
were analyzed and compared with steady-
state levels as measured by ELISA. The
same three animals were evaluated in two
separate studies, and calculated FCRs
were correlated between studies (r 
0.9969; supplemental Fig. 1A, available at
www.jneurosci.org as supplemental ma-
terial). Different individualmonkeys (n
3) also showed similar FCRs with SEM
between 0.3 and 0.5%/h demonstrating
some biological variability between mon-
keys (supplemental Fig. 1B, available at
www.jneurosci.org as supplemental ma-
terial). FSR and FCR results were com-
pared with levels of A. There was a
positive correlation between FSR andFCR
values and levels of A (n 9, FSR vs A
40 Pearson r  0.76, p  0.016; FSR vs
A42 Pearson r  0.77, p  0.015; FCR
vs A 40 Pearson r 0.41, p 0.27; FCR
vs A 42 Pearson r 0.79, p 0.03).
The 12 h optimized 13C6-leucine (4
mg/kg/h) infusion (n  12 monkeys)
demonstrated low intersubject variability
for A labeling kinetics at each time point
sampled over 39 h (average SEM  0.02,
n  12) (Fig. 3A). There were no signifi-
cant differences observed between gen-
ders or across ages of the animals included in this study. The
mean FSR (h 2–8) was 10.7 0.6%/h (SEM) and the mean FCR
(h 18–33) was 9.9  0.5%/h (Fig. 3B); these values were not
significantly different ( p 0.25).
CNS-penetrant -secretase inhibitor decreases the generation
of newly produced A in the brain of rhesus monkeys
In a three-way crossover study, healthy male CMP rhesus mon-
keys (n 6) were treated with single oral administration of two
doses of the CNS-penetrant GSI, MK-0752, and vehicle to evalu-
ate effects on A metabolism. MK-0752 concentrations were
quantified in plasma (Fig. 4A) and CSF (Fig. 5A), showing peak
concentration at 2 h with both doses. The majority of the drug
was cleared from plasma and CSF by 36 h. Effects of this GSI on
A concentrations in the plasma and CSF were quantified using
ELISA and demonstrate a dose-related reduction of A levels in
plasma (A40) ( p  0.0012) and CSF (A40 and A42) ( p 
0.001) as determined by a repeated-measures ANOVA (Figs. 4B,
5B,C). Plasma A levels rebounded above baseline after GSI in-
hibition (60 mg/kg) ( p 0.001 paired t test vehicle vs 60 mg/kg
h 33–48) (Fig. 4B); in contrast, CSF A levels did not overshoot
baseline levels (Figs. 5B,C). In an extended study designed to
evaluate the rebound response of the higher dose of 240 mg/kg,
an overshoot above baseline was observed in plasma 48 h after
treatment ( p  0.001 unpaired t test vehicle vs 240 mg/kg h
48–240) (Fig. 4D).
The GSI dose-dependently reduced newly synthesized CNS
A over 48 h, without any evidence of a rebound or overshoot of
newly generated CNSA (Fig. 6A). Similar results were observed
in an extended study (240 h) with the 240 mg/kg GSI treatment
(Fig. 6B) (unpaired t test, p  0.0009). Area under the curve
(AUC) analysis for newly generated A indicated a significant
difference between the means of the vehicle and GSI treatment
groups (ANOVA, p 0.0001). Themean AUC not only reflected
a dose-dependent decrease during the 13C6-leucine infusion
(0–12 h) (Fig. 6C), but also during the entire study (0–48 h) (Fig.
6D) (Tukey post hoc analysis, p  0.001). During the 48 h sam-
pling period, the mean AUC of newly generated A was reduced
by 49% in the 60mg/kg dose group and by 90% in the 240mg/kg
GSI dose group ( p 0.01) (Fig. 6D).
CNS-penetrant -secretase inhibitor alters levels of
noncanonical APP fragments
To evaluate alternative pathways of APP degradation in the pres-
ence of -secretase inhibition, noncanonical forms of A (e.g.,
A not produced by - and -secretase cleavage) were measured
in theCSF of rhesusmonkeys (n 6, 3/group) treatedwith a high
dose of MK-0752 (240 mg/kg) versus vehicle. Four isoforms of
A (A 1-14, A 1-15, A 1-16, and A 1-17) were quantified
from the CSF using internal standard controls. In animals treated
with the GSI, levels of A 1-14, A 1-15, and A 1-16 increased
over vehicle levels, while levels of A 1-17 decreased (unpaired t
test, p 0.0001, Fig. 7). The expected reductions in plasma A40
and CSF A40 and A42 were demonstrated during the same
time (Figs. 4D, 5E,F), while plasma A40 rebounded after 48 h
(Fig. 4D).
Figure 2. The duration of 13C6-labeling does not affect A production estimates, and plasma better reflects the
13C6-leucine
precursor for A compared with CSF. A, B, Rhesus monkeys (n 3) were infused with 13C6-leucine (8 mg/kg/h) for either 21 h
(black, solid circle) or 12 h (red, solid triangle). The ratio of 13C-A to 12C-A from CSF was measured by LC-MS, and normalized
to the 13C6-leucine precursor enrichment measured in either CSF (A) or plasma (B). Values1 indicate incorrect estimates. Error
bars represent SEM.
Figure 3. Rhesus monkey CNS Ametabolism is similar to results observed in humans (Bateman et al., 2006). A, Optimized
13C6-leucine labelingprotocolwas 4mg/kg/h for 12h, andCSF collected for 39h (n12).B, Rates of Aproduction and clearance
are balanced in the rhesus monkey CNS. Combining results from three studies using identical protocols, the production and
clearance rateswere found tobe consistent acrossn12 rhesusmonkeys. Therewasno significant differencebetween themeans
observed for FSR and FCR, as measured by a Student’s t test. Error bars indicate SEM.
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Discussion
The results of this study demonstrate that Ametabolism in the
rhesus monkey is similar to healthy humans (Bateman et al.,
2006), which is expected because there are no significant amyloid
plaques present in the rhesusmonkey brain at this age (Struble et al.,
1985). In conjunction with in vivo stable-isotope-labeling, new
generation of CNS A was significantly
reduced in response to -secretase inhi-
bition. However, in contrast to the pe-
riphery, production of CNS A did not
rebound above baseline after cessation of
inhibition. Defining the metabolic fate of
APP in the CNS is critically important for
the development of -secretase inhibitors
to treat AD, as a substrate build-up of APP
fragments could potentially lead to an
overshoot in neurotoxic amyloid pep-
tides. The lack of A rebound in the CNS
could be attributed to the shunting of APP
(possibly  C-terminal fragments, e.g.,
C99) to -secretase independent degrada-
tion. In support of this alternative, nonca-
nonical processing, increased levels of
APP fragments A 1-14, 1-15, and 1-16
were observed in CSF samples of ani-
mals treated with the GSI, while A 1-17
was decreased. The CNS elimination of
APP through nonamyloidogenic path-
ways strengthens the case for the use of
-secretase as a therapeutic target for
AD and may also be relevant for physi-
ological processing of APP.
Many treatments have demonstrated
efficacy in preclinical AD murine models;
however, to date, none have been success-
ful in clinical trials (Duff and Suleman,
2004). Failed translation from preclinical
models to clinical studies may be a result
of several reasons, including targeting of
the wrong molecular mechanism of dis-
ease, failure to sufficiently modulate the
target, or administration of the therapy too
late in the course of the disease (Bateman
and Klunk, 2008). For Alzheimer’s dis-
ease, one limiting factor for translation
from preclinical models to clinical trials is
the lack of animal models that closely re-
flect human A CNS physiology; such
models would provide relevant informa-
tion regarding the target, mechanism of
action, and therapeutic effectiveness.
Thus, there is a need to develop better
models of therapeutic targets that would
provide a bridge for the translation ofmu-
rine models of amyloidosis to human tri-
als in AD.
The CMP rhesus monkey is a nonhu-
man primate model that enables repeat
sampling of CSF (Gilberto et al., 2003;
Nantermet et al., 2009; Sankaranarayanan
et al., 2009). Pairing this model with in
vivo SILK enables direct measurement of
newly generatedCNS proteins and peptides
such as A. Results demonstrate that Ametabolism in the rhesus
monkey is very similar to humans (Bateman et al., 2006), which
indicate that theCMPrhesusmonkeymodel canbeused forpreclin-
ical drug discovery and development studies. Repeated measures
(pre- and posttreatment) studies with a crossover design are espe-
cially powerful when coupled with the low intrasubject variability.
Figure 4. Plasma levels of A during and after -secretase inhibition indicate peripheral A rebound in rhesus monkeys
treated with a CNS-penetrant GSI. A, Concentration of GSI in rhesus monkey plasma after dosing with GSI. B, A levels in rhesus
monkeys (n 6), measured by ELISA are shown normalized to baseline. A dose–response effect on A levels was observed with
60mg/kg and240mg/kg. PlasmaA levels in the 60mg/kgdose group recovered to baseline after 24 h, and then increased above
baseline. Means between vehicle and 60mg/kg from hours 33–48 are significantly different (paired t test, ***p 0.0001). C,D,
In anextended study (n6, 3/group), animalswere treatedwith either vehicle or 240mg/kgGSI.C, ConcentrationofGSI in rhesus
monkey plasma after dosing with 240 mg/kg GSI. D, Plasma A levels overshoot baseline after 48 h in 240 mg/kg GSI-treated
animals (unpaired t test, ***p 0.0001, h48–240). (vehicle, black circle; 60mg/kg, blue square; 240mg/kg, red triangle). Error
bars indicate SEM.
Figure 5. No evidence of central A rebound in rhesus monkeys treated with a CNS-penetrant GSI. A, Concentration of GSI in
rhesus monkey CSF after dosing. B, C, A levels in rhesus monkeys (n 6), measured by ELISA, were normalized to baseline. A
dose–response effect on A levels was observedwith GSI treatment. A rebound effect was not observed in levels of CSF A40 (B)
or A42 (C). After 48 h, the A levelswith 240mg/kg treatment only recovered to 50%of baseline,while the 60mg/kg treatment
group reached baseline at 30 h without overshoot. D–F, In an extended study (n 6, 3/group) A levels returned to baseline
within 72 h of treatment (240 mg/kg), without rebound. (vehicle, black circle; 60 mg/kg, blue square; 240 mg/kg, red triangle).
Error bars indicate SEM.
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This combinationallows for theuseof fewer
monkeys to clearly answer research ques-
tions (Fig. 3; supplemental Fig. 1, available
at www.jneurosci.org as supplemental
material).
There are similarities and differences be-
tween themetabolismofA in rhesusmon-
keys and humans. As expected, the average
FSR and FCR are balanced in both the rhe-
sus monkey (n 12) (Fig. 3B) and human
(Bateman et al., 2006). However, rhesus
monkey CNS FSR and FCR are slightly
faster than human CNS FSR and FCR
(10% per hour vs8% per hour, respec-
tively; Fig. 3B) (Bateman et al., 2006).Other
than species differences, the observed dis-
parity inAmetabolismmay be due toCSF
sampling location. Human CSF was sam-
pledby lumbar intrathecal catheter,whereas
monkey CSF was sampled at the cisterna
magna at the base of the head (Fig. 1A). The
moreproximal sampling locationcouldalso
explain the slightly shorter delay in 13C6 in-
corporationobserved in themonkeysversus
that seen in humans (4 h vs 5 h, respec-
tively), which indicates that lumbar sam-
pling only slightly delays the appearance of
newly generated A. Prior human studies
demonstrated individual changes inCSFA
levels by 100–400% over several hours
(Batemanet al., 2007a). In this studyofnon-
human primate CSF, there were individual
CSF A changes of 30–50%. The group
changes in A levels were similar between
human lumbar CSF samples and nonhu-
man primate CMP samples when averaged
(25–50% over a 24 h period). However,
CMPmonkey samples did not demonstrate
a progressive rise inA levels. Possible rea-
sons for differences in the intrasubject
CSF A variability and lack of CSF A
rise include species differences, behavioral
activity, site of sampling, frequency or
amount of sampling, and sleep/wake cycle
differences.
Findings in the nonhuman primate
model also have implications for human
studies. For example, in this study, we de-
termined that plasma is more accurate
than CSF for leucine precursor measure-
ments of CNS A generation (Fig. 2). As
the CSF normalized ratio exceeded the
theoretical maximum of one, the CSF
13C6-leucine is an underestimate of the
precursor pool labeling. The labeled
leucine precursor enrichment in monkey
plasma is higher than CSF, similar to re-
sults observed in humans (Bateman et al.,
2006). This suggests that plasma-labeled
leucine measurements are more accurate
for calculations of A metabolism in hu-
man, as well as the nonhuman primate.
Figure 6. Newly generated Awas reduced in response to GSI treatment in the CNS of rhesus monkeys (n 6). A, C, D,
In a crossover study, male rhesus monkeys (n 6) were infused with 13C6-leucine (4 mg/kg/h) for 12 h, and treated with
vehicle (black circle), 60mg/kg GSI (blue square), or 240mg/kg GSI (red triangle).B, In an extended study (n 6, 3/group),
animals were treated with vehicle or 240 mg/kg GSI. A, B, Generation of new Awas partially blocked with administration
of 60 mg/kg, and nearly completely blocked at the 240 mg/kg dose as indicated by the dose-dependent decrease in the
amount of 13C6-leucine-labeled A (LC-MS). C, D, AUC analysis of newly generated A indicates that the means of newly
synthesized A are significantly reduced by GSI treatment during the leucine infusion (0 –12 h) (C) and levels do not
recover within 48 h (D), as assessed by a repeated measures 1-way ANOVA ( p 0.0001) and post hoc analysis (Tukey)
(*p 0.01 to 0.05;**p 0.001 to 0.01; ***p 0.001). Error bars indicate SEM.
Figure 7. -Secretase inhibition modulates levels of A 1-14, 1-15, 1-16, and 1-17. Rhesus monkeys (n 6, n 3/group)
were treated with either vehicle (black, circle) or 240mg/kg GSI (red, triangle). An increase in levels of A 1-14 (A), A 1-15 (B),
and A 1-16 (C) was observed in GSI versus vehicle-treated animals during-secretase inhibition. However, levels of A 1-17 (D)
in treated animals were decreased versus vehicle. The means of the vehicle versus treated animals over 48 h were significantly
different for A 1-14 (A), A 1-15 (B), A 1-16 (C), and A 1-17 (D) (unpaired t test p 0.0001).
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The utility of this CMP rhesus monkey translational model
was demonstrated by quantifying Ametabolism before and af-
ter acute exposure to the GSIMK-0752. A prior humanGSI SILK
study indicates that a decrease in A production can bemeasured
to a sensitive degree (Bateman et al., 2009). In this nonhuman
primate study, GSI efficacy (blocking A production) and dura-
tion was higher compared with that observed in the human GSI
study. Possible reasons for these observed differences include the
GSI compoundused, the dose ofGSI administered, and, possibly,
species differences. The extended effect may be due to the longer
half-life of MK-0752 (10 h) in rhesus monkey versus LY450139
(2.5 h) in human (Siemers et al., 2005).
Consistentwith previous observations (Lanz et al., 2004, 2006;
Michener et al., 2006; Rosen et al., 2006; Siemers et al., 2006;
Burton et al., 2008) plasma A levels did rebound after the GSI
was cleared (Fig. 4). However, concentrations of A in the CSF
did not overshoot baseline or placeboA levels (Fig. 5).Measure-
ment of production rates directly confirms that this GSI reduced
A levels by decreasing the generation of new A without a sub-
sequent rebound (Fig. 6). These results suggest that the A pre-
cursor is being degraded by another pathway during inhibition
(Portelius et al., 2009). In vitro studies have suggested that in the
presence of -secretase inhibition, -secretase and -secretase
generate A 1-14, 1-15, and 1-16, and that A isoforms longer
than 1-16 are reduced (Portelius et al., 2009). Our results support
this hypothesis by demonstrating for the first time in a nonhu-
man primate model, the rise in A 1-14, 1-15, and 1-16 with a
concurrent decrease of A 1-17 (Fig. 7). Further, the time course
of altered APP metabolites indicates that A 1-17 is possibly a
cleavage product of A 1-40 and A 1-42, as all are decreased at
similar times (0–48 h), while A 1-14, 1-15, and 1-16 are in-
creased during and after inhibition (0–144 h). Potential candi-
dates known to cleave at the A 1-17 site include endothelin
converting enzyme, insulin-degrading enzyme, andmatrixmetallo-
proteinase-9 (Yan et al., 2006). These findings advance our under-
standing of the mechanisms of APP processing in the CNS, and
provide novel information about the effects of GSI therapy on APP
processing.
In conclusion, our study demonstrates that the effect of ther-
apeutics developed to target A production or clearance can be
evaluated directly in a preclinical, nonhuman primate model.
This will aid in the selection of clinical candidate compounds,
and optimization of dose and timing of drug administration in a
model which is similar to human A physiology. In addition,
molecular mechanisms of CNS protein processing can be ex-
plored by using therapeutics, which modulate key CNS enzymes
with physiologically relevant models. These methods and find-
ings hold promise to improve the likelihood of successful clinical
trials for the treatment of Alzheimer’s disease and other CNS
disorders.
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